Digital Science boosts pharma industry support following OntoChem acquisition

Digital Science is positioning itself to play an even greater role in the pharmaceutical industry’s all-important drug discovery, by helping industry sift through a sea of information and focus on the research that matters.

Over half of top selling Medicare drugs have low added therapeutic benefit

Brand-name drugs cost two to three times more in the U.S. than in other countries, but many of the top-selling brand name drugs may provide little added therapeutic benefit. A new study led by researchers at Brigham and Women’s Hospital, a founding member of Mass General Brigham, used public Medicare data to identify the 50 highest-selling brand-name drugs in 2020.

Degrading modified proteins could treat Alzheimer’s, other ‘undruggable’ diseases

A new technique that targets and breaks apart certain proteins — rather than just interfering with them — may offer a pathway toward treatment of Alzheimer’s disease. Researchers reporting in ACS Central Science have designed a compound that breaks down a protein closely associated with the disease.

Multiplication on, multiplication off: Targeting an enzymatic switch to develop oncology drugs

Interdisciplinary research highlighted lipid-protein interaction as a new avenue for oncology drug development, demonstrating its functionality by designing small molecule-based inhibitors to target acute myeloid leukemia.

With High Costs and Similar Benefits, Use of New Neurology Drugs Is Low

A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson’s disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having higher out-of-pocket costs and benefits similar to existing, less expensive drugs, only a small percentage of people with neurologic conditions are being treated with these new drugs, according to a study funded by the American Academy of Neurology and published in the November 30, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Social support promotes rehab participation in mice after spinal cord injury

A research finding in mice that gabapentin improved rehab compliance after spinal cord injury led scientists to a related, unexpected discovery: Injured mice that didn’t receive the drug and declined to exercise by themselves were willing to hop on the treadmill for a group rehab option.

UNH Research Finds Repurposed Drug Inhibits Enzyme Related to COVID-19

With the end of the pandemic seemingly nowhere in sight, scientists are still very focused on finding new or alternative drugs to treat and stop the spread of COVID-19. In a first-of-its-kind study, researchers at the University of New Hampshire have found that using an already existing drug compound in a new way, known as drug repurposing, could be successful in blocking the activity of a key enzyme of the coronavirus, or SARS-CoV-2, which causes COVID-19.